A phase II-III randomized trial evaluating maintenance pembrolizumab (± pemetrexed) until progression versus observation (± pemetrexed) after 6 months of platinum-based doublet chemotherapy plus pembrolizumab induction treatment in patients with stage IV Non-Small Cell Lung Cancer (NSCLC)

Status: Recruiting

Phase of Trial: Phase II/III

Latest Information Update: 04 Apr 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Pembrolizumab (Primary) ; Pemetrexed (Primary) ; Carboplatin; Cisplatin; Paclitaxel
Indications Non-small cell lung cancer
Focus Therapeutic Use
Acronyms DIAL

Most Recent Events

26 Mar 2025 Planned primary completion date changed from 1 Jan 2025 to 1 May 2025.
18 Oct 2024 Planned primary completion date changed from 1 Jun 2024 to 1 Jan 2025.
28 Sep 2023 Planned primary completion date changed from 1 Jun 2023 to 1 Jun 2024.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com

Welcome to AdisInsight